Presentation of Zerion Pharma by CEO Ole Viborg and CFO Jakob Dynes Hansen

Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round.

Terms:

Closing date 15th. of March 2023, Lot size € 33t and pre-money valuation € 14m.

Contact: CEO Ole Wiborg - ow@zerion.eu or CFO Jakob Dynnes Hansen - jdh@zerion.eu if you are interested to subscribe and further details.

In the first interview, management will run through the investment proposal and business case. This is a general introduction to the case:

Watch here: https://www.inderes.dk/en/videos/zerion-pharma-company-introduction

In the second interview, management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs.
Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Watch here: https://www.inderes.dk/en/videos/zerion-pharma-regulatory-environment-and-strategic-partnerships

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company and is not listed on a regulated stock market. Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise.